| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8790043 | Urologic Oncology: Seminars and Original Investigations | 2018 | 7 Pages |
Abstract
This in vivo study confirms the safety of intravesical TMX-101 and TMX-202 administration, with TMX-202 showing lower systemic uptake. TMX-202 has a larger molecule-mass compared to TMX-101, and it may therefore have a favorable safety profile when treating patients with non-muscle-invasive bladder cancer intravesically.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
Johannes M.D., Christina A. M.D., Ph.D., Roberto PharmD., Egbert Ph.D., Johannes Alfred M.D., Ph.D.,